97939674 - FUSOGENIX

Information

• Trademark
• 97939674

• Source

• Serial Number

  97939674

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  May 16, 2023
  a year ago

• Transaction Date

  November 18, 2024
  a month ago

• Status Date

  November 17, 2024
  a month ago

• Location Date

  November 17, 2024
  a month ago

• Status Code

  651

• Current Location

  TMO LAW OFFICE 129

  Employee Name

  HENRY, NAKIA

• Attorney Docket Number

  079440.00021

  Attorney Name

  Theodore R. Remaklus

  Law Office Assigned Location Code

  O20

• Owners

  • ENTOS PHARMACEUTICALS INC

Case File Statements

• GS0401: Custom manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies
• GS0051: Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems namely, the lung in the nature of pneumonia, kidneys in the nature of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers in the nature of hematological cancers and solid organ cancers; vaccines that are viral, bacterial, fungal for human use; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely Crohn's and ulcerative colitis, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; Drug delivery system, comprising FAST proteins for intracellular delivery of therapeutic agents; drug delivery system, comprising naturally occurring, engineered and FAST proteins fused to antibodies, polypeptide sequences and targeting ligands, namely, Alpha-V/Beta3, RGD, EGFL7, PC3, Hepsin, Protease cleaved collagen IV and Plectin, for intracellular delivery of therapeutic agents; drug delivery system, comprising charged, ionizable and cationic lipids to neutralize nucleic acid cargo(es) and overall particle charge for intracellular delivery of therapeutic agents; drug delivery system, comprising helper lipids to mediate particle morphology, structure, fluidity and FAST protein stabilization for intracellular delivery of therapeutic agents; drug delivery system, comprising conjugated lipids, namely, pegylated lipids for stability and size, and cargoes, namely, DNA, plasmid DNA, circular DNA, single stranded DNA, RNA, mRNA, siRNA, miRNA, shRNA, tRNA, protein, peptides, small molecules, and combinations thereof for intracellular delivery of therapeutic agents; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and therapeutic agents
• GS0011: Diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use
• GS0441: Medical therapy services, namely gene therapy services; medical analysis services, namely RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes
• GS0421: Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticals, therapeutic agents and medical devices; research and product development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates

Case File Event Statements

• 5/19/2023 - a year ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 6/15/2023 - a year ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 6/26/2023 - a year ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 6/27/2023 - a year ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 6/27/2023 - a year ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 6/27/2023 - a year ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 6/27/2023 - a year ago

  7 - NON-FINAL ACTION WRITTEN Type: CNRT

• 6/27/2023 - a year ago

  8 - NON-FINAL ACTION E-MAILED Type: GNRT

• 6/27/2023 - a year ago

  9 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 9/27/2023 - a year ago

  10 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Type: XELR

• 9/27/2023 - a year ago

  11 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Type: XELG

• 10/25/2023 - a year ago

  12 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 10/25/2023 - a year ago

  13 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 10/26/2023 - a year ago

  14 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 11/17/2023 - a year ago

  15 - SUSPENSION LETTER WRITTEN Type: CNSL

• 11/17/2023 - a year ago

  16 - LETTER OF SUSPENSION E-MAILED Type: GNSL

• 11/17/2023 - a year ago

  17 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3

• 10/7/2024 - 3 months ago

  18 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR

• 10/7/2024 - 3 months ago

  22 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 10/7/2024 - 3 months ago

  21 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 10/7/2024 - 3 months ago

  19 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN

• 10/7/2024 - 3 months ago

  20 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 11/17/2024 - a month ago

  26 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2

• 11/17/2024 - a month ago

  25 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI

• 11/17/2024 - a month ago

  24 - SUSPENSION INQUIRY WRITTEN Type: CNSI

• 10/17/2024 - 2 months ago

  23 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK